CL2016002941A1 - Conjugación en sitio específico de fármacos enlazadores con anticuerpos y conjugados de anticuerpo-fármaco (adc) resultantes. - Google Patents
Conjugación en sitio específico de fármacos enlazadores con anticuerpos y conjugados de anticuerpo-fármaco (adc) resultantes.Info
- Publication number
- CL2016002941A1 CL2016002941A1 CL2016002941A CL2016002941A CL2016002941A1 CL 2016002941 A1 CL2016002941 A1 CL 2016002941A1 CL 2016002941 A CL2016002941 A CL 2016002941A CL 2016002941 A CL2016002941 A CL 2016002941A CL 2016002941 A1 CL2016002941 A1 CL 2016002941A1
- Authority
- CL
- Chile
- Prior art keywords
- cancer
- antibody
- drug
- adc
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17021—Glutamate carboxypeptidase II (3.4.17.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
<p>Conjugados de anticuerpo-fármaco (ADC) en que un fármaco enlazador se conjuga con un anticuerpo en un sitio específico a través de una cisteína diseñada, y su uso como medicamento, principalmente en el tratamiento de tumores sólidos humanos y neoplasias hematológicas, específicamente cáncer de mama, cáncer gástrico, cáncer colorrectal, cáncer urotelial, cáncer de ovarios, cáncer uterino, cáncer pulmonar, mesotelioma, cáncer hepático, cáncer pancreático, cáncer prostático y leucemia.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14169493 | 2014-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016002941A1 true CL2016002941A1 (es) | 2017-12-22 |
Family
ID=50771151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016002941A CL2016002941A1 (es) | 2014-05-22 | 2016-11-18 | Conjugación en sitio específico de fármacos enlazadores con anticuerpos y conjugados de anticuerpo-fármaco (adc) resultantes. |
Country Status (22)
Country | Link |
---|---|
US (4) | US10407743B2 (es) |
EP (3) | EP3868379A1 (es) |
JP (2) | JP6517240B2 (es) |
KR (1) | KR102419766B1 (es) |
CN (1) | CN106456794B (es) |
AU (2) | AU2015261768B2 (es) |
CA (1) | CA2947238A1 (es) |
CL (1) | CL2016002941A1 (es) |
CY (1) | CY1125232T1 (es) |
DK (1) | DK3151865T3 (es) |
ES (1) | ES2895623T3 (es) |
HR (1) | HRP20211710T1 (es) |
HU (1) | HUE056023T2 (es) |
LT (1) | LT3151865T (es) |
MX (1) | MX2016015176A (es) |
MY (1) | MY183480A (es) |
PL (1) | PL3151865T3 (es) |
PT (1) | PT3151865T (es) |
RU (1) | RU2670157C2 (es) |
SG (2) | SG11201609372UA (es) |
WO (1) | WO2015177360A1 (es) |
ZA (1) | ZA201607109B (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
LT2560645T (lt) | 2010-04-21 | 2016-10-10 | Syntarga B.V. | Cc-1065 analogų ir bifunkcinių linkerių konjugatai |
KR20160099725A (ko) | 2014-01-10 | 2016-08-22 | 신톤 바이오파머슈티칼즈 비.브이. | 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc |
RU2769700C2 (ru) | 2014-01-10 | 2022-04-05 | Байондис Б.В. | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo |
EP3868379A1 (en) * | 2014-05-22 | 2021-08-25 | Byondis B.V. | Site-specific conjugation of linker drugs to antibodies and resulting adcs |
JP6275881B2 (ja) | 2014-06-05 | 2018-02-07 | シントン・バイオファーマシューティカルズ・ビー.ブイ.Synthon Biopharmaceuticals B.V. | デュオカルマイシンのプロドラッグを製造するための改良された方法 |
BR112018010394A8 (pt) | 2015-11-24 | 2019-02-26 | Synthon Biopharmaceuticals Bv | anticorpo, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação do anticorpo. |
CN110606890B (zh) * | 2015-12-24 | 2021-11-26 | 凯惠科技发展(上海)有限公司 | 一种tpbg抗体及其制备方法、其偶联物和应用 |
EP3411075A1 (en) * | 2016-02-05 | 2018-12-12 | Millennium Pharmaceuticals, Inc. | Gcc-targeted antibody-drug conjugates |
PT3458100T (pt) * | 2016-02-12 | 2020-08-05 | Byondis Bv | Redução seletiva de anticorpos modificados por cisteína |
JP7179719B2 (ja) | 2016-06-06 | 2022-11-29 | ポリセリックス・リミテッド | 抗体、その使用及びそのコンジュゲート |
WO2018006785A1 (zh) * | 2016-07-05 | 2018-01-11 | 江苏恒瑞医药股份有限公司 | Egfr抗体-药物偶联物及其在医药上的应用 |
GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
EP3525826B1 (en) | 2016-10-11 | 2020-07-22 | Byondis B.V | Non-linear self-immolative linkers and conjugates thereof |
KR102614466B1 (ko) | 2016-11-14 | 2023-12-14 | 비온디스 비.브이. | 단일-보호된 알파, 오메가-디아미노 알칸의 제조 방법 |
SG10201912879YA (en) | 2016-12-09 | 2020-02-27 | Alector Llc | Anti-sirp-alpha antibodies and methods of use thereof |
CN108285487B (zh) * | 2017-01-08 | 2021-02-19 | 浙江昭华生物医药有限公司 | 抗5t4抗体-药物偶联物及其应用 |
CA3050085A1 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
JOP20190187A1 (ar) * | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
WO2018187791A1 (en) | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
WO2018215427A1 (en) | 2017-05-23 | 2018-11-29 | Synthon Biopharmaceuticals B.V. | Dual conjugation process for preparing antibody-drug conjugates |
KR20200012937A (ko) * | 2017-06-06 | 2020-02-05 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | c-Met 항체 약물 접합체를 포함하는 약학 조성물 및 그의 용도 |
EP3634485A4 (en) * | 2017-06-07 | 2021-07-21 | Silverback Therapeutics, Inc. | CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES |
CA3066920A1 (en) * | 2017-06-16 | 2018-12-20 | Eli Lilly And Company | Engineered antibody compounds and conjugates thereof |
WO2019046859A1 (en) * | 2017-09-02 | 2019-03-07 | Abbvie Inc. | ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF |
EP3678682A4 (en) * | 2017-09-06 | 2021-06-09 | Airway Therapeutics, Inc. | METHOD, COMPOSITIONS AND CELLS FOR MANUFACTURING SURFACTANT PROTEIN D (SP-D) |
KR20200044955A (ko) | 2017-09-06 | 2020-04-29 | 에어웨이 테라퓨틱스, 아이엔씨. | 계면활성제 단백질 d (sp-d)를 제조하는 방법 및 조성물 |
DK3713939T3 (da) | 2017-11-24 | 2021-09-13 | Byondis Bv | Forbedret fremgangsmåde til syntese af linker-lægemidlet vc-seco |
CA3083345A1 (en) * | 2017-11-27 | 2019-05-31 | Purdue Pharma L.P. | Humanized antibodies targeting human tissue factor |
CN108187065B (zh) * | 2017-12-29 | 2023-04-28 | 广东众生药业股份有限公司 | 抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途 |
IL277049B2 (en) | 2018-03-13 | 2024-02-01 | Zymeworks Bc Inc | Conjugates of biparatopic anti-HER2 antibody and drug and methods of use |
MA52135A (fr) * | 2018-03-23 | 2021-01-27 | Seagen Inc | Utilisation de conjugués anticorps-médicament comprenant des agents de rupture de tubuline pour traiter une tumeur solide |
EP3802602A1 (en) | 2018-05-25 | 2021-04-14 | Alector LLC | Anti-sirpa antibodies and methods of use thereof |
EP3836950A4 (en) * | 2018-08-16 | 2022-04-06 | Genmab A/S | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER |
US20200289663A1 (en) * | 2018-08-29 | 2020-09-17 | Remegen, Ltd | Use of anti-her2 antibody-drug conjugate in treating urothelial carcinoma |
US20210393791A1 (en) * | 2018-10-31 | 2021-12-23 | Health Research, Inc. | Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor |
BR112021008293A2 (pt) | 2018-11-09 | 2021-08-03 | Byondis B.V. | composição, método, e, método para liberar/aprovar um lote de conjugado de anticorpo-fármaco |
CN111675762B (zh) * | 2019-03-11 | 2023-12-01 | 凯惠科技发展(上海)有限公司 | 一种含半胱氨酸的抗体、药物偶联物及其应用 |
WO2021066869A1 (en) | 2019-10-04 | 2021-04-08 | TAE Life Sciences | Antibody compositions comprising fc mutations and site-specific conjugation properties |
BR112022015062A2 (pt) | 2020-02-06 | 2022-09-20 | Byondis Bv | Conjugado anticorpo-fármaco para uso no tratamento de um tumor, composição, uso de um conjugado anticorpo-fármaco, produto compreendendo um conjugado anticorpo-fármaco, e, método para prevenção ou redução da toxicidade associada à administração de um conjugado anticorpo-fármaco |
MX2023000376A (es) | 2020-07-06 | 2023-04-18 | Byondis Bv | Fármacos de enlazador de antifolato, y conjugados de anticuerpo-fármaco. |
CN116761824A (zh) * | 2021-01-18 | 2023-09-15 | 上海药明合联生物技术有限公司 | 工程化抗-trop2抗体及其抗体-药物偶联物 |
JP2024515266A (ja) | 2021-04-08 | 2024-04-08 | ビョンディス・ビー.ブイ. | 抗c-MET抗体及び抗体薬物複合体 |
CA3223936A1 (en) | 2021-06-28 | 2023-01-05 | Ronald Christiaan Elgersma | Conjugates comprising phosphoantigens and their use in therapy |
CN114106180B (zh) * | 2021-12-13 | 2023-07-28 | 中国药科大学 | 一种单克隆抗体及其应用 |
WO2023126297A1 (en) | 2021-12-30 | 2023-07-06 | Byondis B.V. | Antifolate linker-drugs and antibody-drug conjugates |
WO2023222580A1 (en) | 2022-05-16 | 2023-11-23 | Byondis B.V. | Novel masked antibodies |
WO2024027795A1 (zh) * | 2022-08-04 | 2024-02-08 | 苏州开拓药业股份有限公司 | 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
CN116212045A (zh) * | 2023-03-31 | 2023-06-06 | 温州医科大学 | 靶向癌细胞表面muc1的新型抗体药物偶联物及其制备方法与应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
IL158969A0 (en) | 2001-06-01 | 2004-05-12 | Cornell Res Foundation Inc | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
BRPI0515113A (pt) * | 2004-09-10 | 2008-07-01 | Wyeth Corp | anticorpos anti-5t4 humanizados e conjugados de anticorpo anti-5t4/caliqueamicina |
ES2579805T3 (es) * | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
AU2006262231B2 (en) | 2005-06-20 | 2013-01-24 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
NZ566982A (en) * | 2005-09-26 | 2011-06-30 | Medarex Inc | Duocarmycin drug conjugates |
ES2712942T3 (es) | 2006-03-10 | 2019-05-16 | Wyeth Llc | Anticuerpos anti-5T4 y usos de los mismos |
US8680293B2 (en) | 2007-08-01 | 2014-03-25 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
PL2344478T3 (pl) | 2008-11-03 | 2018-02-28 | Syntarga B.V. | Analogi CC-1065 oraz ich koniugaty |
RU2673908C2 (ru) | 2009-12-02 | 2018-12-03 | Имэджинэб, Инк. | Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения |
LT2560645T (lt) | 2010-04-21 | 2016-10-10 | Syntarga B.V. | Cc-1065 analogų ir bifunkcinių linkerių konjugatai |
WO2012131527A1 (en) * | 2011-04-01 | 2012-10-04 | Wyeth Llc | Antibody-drug conjugates |
CA3111357A1 (en) * | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
EP2906250B1 (en) * | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
AU2014214751B2 (en) | 2013-02-08 | 2017-06-01 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
RU2769700C2 (ru) | 2014-01-10 | 2022-04-05 | Байондис Б.В. | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo |
KR20160099725A (ko) | 2014-01-10 | 2016-08-22 | 신톤 바이오파머슈티칼즈 비.브이. | 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc |
KR102323301B1 (ko) | 2014-01-10 | 2021-11-09 | 비온디스 비.브이. | Cys 연결된 항체-약물 접합체의 정제 방법 |
EP3868379A1 (en) * | 2014-05-22 | 2021-08-25 | Byondis B.V. | Site-specific conjugation of linker drugs to antibodies and resulting adcs |
JP6275881B2 (ja) | 2014-06-05 | 2018-02-07 | シントン・バイオファーマシューティカルズ・ビー.ブイ.Synthon Biopharmaceuticals B.V. | デュオカルマイシンのプロドラッグを製造するための改良された方法 |
US20170320965A1 (en) | 2014-09-22 | 2017-11-09 | Synthon Biopharmaceuticals B.V. | Pan-reactive antibodies to duocarmycins |
-
2015
- 2015-05-22 EP EP21161774.1A patent/EP3868379A1/en active Pending
- 2015-05-22 WO PCT/EP2015/061456 patent/WO2015177360A1/en active Application Filing
- 2015-05-22 JP JP2016568847A patent/JP6517240B2/ja active Active
- 2015-05-22 CN CN201580026468.0A patent/CN106456794B/zh active Active
- 2015-05-22 EP EP19160619.3A patent/EP3539544A1/en active Pending
- 2015-05-22 PT PT157246380T patent/PT3151865T/pt unknown
- 2015-05-22 PL PL15724638T patent/PL3151865T3/pl unknown
- 2015-05-22 KR KR1020167036019A patent/KR102419766B1/ko active IP Right Grant
- 2015-05-22 DK DK15724638.0T patent/DK3151865T3/da active
- 2015-05-22 US US15/312,436 patent/US10407743B2/en active Active
- 2015-05-22 ES ES15724638T patent/ES2895623T3/es active Active
- 2015-05-22 RU RU2016150377A patent/RU2670157C2/ru active
- 2015-05-22 HR HRP20211710TT patent/HRP20211710T1/hr unknown
- 2015-05-22 SG SG11201609372UA patent/SG11201609372UA/en unknown
- 2015-05-22 MY MYPI2016001883A patent/MY183480A/en unknown
- 2015-05-22 HU HUE15724638A patent/HUE056023T2/hu unknown
- 2015-05-22 CA CA2947238A patent/CA2947238A1/en active Pending
- 2015-05-22 LT LTEPPCT/EP2015/061456T patent/LT3151865T/lt unknown
- 2015-05-22 AU AU2015261768A patent/AU2015261768B2/en active Active
- 2015-05-22 MX MX2016015176A patent/MX2016015176A/es active IP Right Grant
- 2015-05-22 SG SG10201913977TA patent/SG10201913977TA/en unknown
- 2015-05-22 EP EP15724638.0A patent/EP3151865B1/en active Active
-
2016
- 2016-10-14 ZA ZA2016/07109A patent/ZA201607109B/en unknown
- 2016-11-18 CL CL2016002941A patent/CL2016002941A1/es unknown
-
2019
- 2019-01-11 JP JP2019003501A patent/JP6900408B2/ja active Active
- 2019-06-28 US US16/457,244 patent/US11104968B2/en active Active
- 2019-06-28 US US16/457,186 patent/US11136633B2/en active Active
-
2020
- 2020-01-09 AU AU2020200175A patent/AU2020200175B2/en active Active
-
2021
- 2021-08-23 US US17/409,462 patent/US20210388115A1/en active Pending
- 2021-11-29 CY CY20211101044T patent/CY1125232T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016002941A1 (es) | Conjugación en sitio específico de fármacos enlazadores con anticuerpos y conjugados de anticuerpo-fármaco (adc) resultantes. | |
NZ741261A (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
HK1259487A1 (zh) | 特定的共軛連接子,特定的免疫共軛物,製造和使用這些共軛物的方法 | |
ECSP19044625A (es) | Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas | |
CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
CR20150488A (es) | Conjugados fármaco-anticuerpo | |
MX2021008334A (es) | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. | |
EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
MX2018002166A (es) | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. | |
CL2017000170A1 (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
MX2016007851A (es) | Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos. | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
MX2016001862A (es) | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento. | |
EA201691963A1 (ru) | Производные тубулизина | |
MX2016007578A (es) | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. | |
MY181960A (en) | Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
CL2018002050A1 (es) | Conjugados anticuerpo-fármaco dirigidos a gcc. | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
SG10202105348WA (en) | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof |